The effectiveness of 124I PET/CT in patients with differentiated thyroid cancer

Quarterly Journal of Nuclear Medicine and Molecular Imaging

Volumn 53, Issue 5, 2009, Pages 536-545

  Capoccetti, F ^a   Criscuoli, B ^a   Rossi, G ^a   Ferreiti, F ^a   Manni, C ^a   Brianzoni, E ^a  

^a MACERATA HOSPITAL   (Italy)

Author keywords

Positron emission tomography; Thyroid neoplasms; Tomography; X ray computed

Indexed keywords

IODINE 124; RECOMBINANT THYROTROPIN; THYROTROPIN; DIAGNOSTIC AGENT; RADIOACTIVE IODINE;

ADOLESCENT; ADULT; AGED; ARTICLE; BONE METASTASIS; CANCER STAGING; CLINICAL TRIAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DIFFERENTIATED THYROID CANCER; DOSIMETRY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HORMONAL THERAPY; HUMAN; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; RADIATION DOSE; THYROID CANCER; THYROIDITIS; WHOLE BODY SCINTISCANNING; ABLATION THERAPY; COMPUTER ASSISTED TOMOGRAPHY; METASTASIS; MIDDLE AGED; PATHOLOGY; PERSONALIZED MEDICINE; POSITRON EMISSION TOMOGRAPHY; RADIOACTIVITY; RADIOGRAPHY; RADIOMETRY; SCINTISCANNING; THYROID TUMOR;

ABLATION TECHNIQUES; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; INDIVIDUALIZED MEDICINE; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; RADIOACTIVITY; RADIOMETRY; THYROID NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED; YOUNG ADULT;

EID: 76349108282     PISSN: 18244785     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Luster M, Clarke SE, Dietlein M, Lassmann M, Lind P, Oyen J Tennvall et al. Guideline for radioiodine therapy of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging 2008;35:1941-59.
2. Benua RS, Cicale NR, Sonenberg M, Rawson RW. The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer. Am J Roentgenol 1962;87:171-82.
3. Rubino C, de Vathaire F, Dottorini ME, Hall P, Schvartz C, Couette JE et al. Second primary malignancies in thyroid cancer patient. Br J Cancer 2003;89:1638-44.
4. Pacini F, Molinaro E, Castagna MG, Lippi F, Ceccarelli C, Agate L et al. Ablation of thyroid residues with 30 mCi (131)I: a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal. J Clin Endocrinol Metab 2002;87:4063-8.
5. Pilli T, Brianzoni E, Capoccetti F, Castagna MG, Fattori S, Rossi G et al. A comparison of 1850 MBq (50 mCi) and 3700 MBq (100 mCi) 131iodine administered doses for recombinant ablation in differentiated thyroid cancer. J Clin Endocrinol Metab 2007;92:3542-6.
6. Mallick U, Harmer C, Hackshaw A. The HiLo trial: a multicentre randomised trial of high- versus low-dose radioiodine, with or without recombinant human thyroid stimulating hormone, for remnant ablation after surgery for differentiated thyroid cancer. Clin Oncol (R Coll Radiol) 2008;20:325-6.
7. 131I activity for remnant ablation in patients with differentiated thyroid cancer: A systematic review. J Clin Endocrinol Metab 2007;92:28-38.
8. 124I-PET dosimetry in advanced differentiated thyroid cancer: therapeutic impact Nuklearmedizin 2007;46:121-8.
9. Biersack HG, Grunwald F. Thyroid cancer. Berlin: Springer Verlag; 2005.
10. 131I diagnostic whole-body scanning. J Nucl Med 2001;42:986-7.
11. 131I preablation imaging before radioiodine ablation in differentiated thyroid carinoma, J Nucl Med 2007;48:1043-6.
12. MIRD Primer for absorbed dose calculation, MIRD Committee. Publications of the Society of Nuclear Medicine, Madison Avenue NY 10016.
13. Linee guida SIE-AIMN-AIFM per il trattamento e follow-up del carcinoma differenziato della tiroide; 2004. p. 11-4.
14. Jentzen W, Freudenberg L, Eising EG, Heinze M, Brandau W, Bockisch A Segmentation of PET volumes by iterative image thresholding. J Nucl Med 2007;48:108-14.
15. Jentzen W, Weise R, Kupferschläger J, Freudenberg L, Brandau W, Bares R et al. Iodine-124 PET dosimetry in differentiated thyroid cancer: recovery coefficient in 2D and 3D modes for PET(/CT) systems. Eur J Nucl Med Mol Imaging 2008;35:611-23.
16. 124I-PET in patients with differentiated thyroid cancer.Eur J Nucl Med Mol Imaging 2008;35:958-65.
17. 124I-PET/CT in staging of patients with differentiated thyroid cancer. Eur Radiol 2004;14:2092-8.
18. 124I PET. Eur J Nucl Med Mol Imaging 2008;35:502-8.
19. Eschmann SM, Reischl G, Bilger K, Kupferschläger J, Thelen MH, Dohmen BM et al. Evaluation of dosimetry of radioiodine therapy in benign and malignant thyroid disorders by means of iodine-124 and PET. Eur J Nucl Med Mol Imaging 2002;29:760-7.
20. Johansson L, Mattsson S, Nosslin B, Leide-Svegborn S. Effective dose from radiopharmaceuticals.Eur J Nucl Med 1992;19:933-8. Erratum in: Eur J Nucl Med 1993;20:570.